Pfizer director and Gbank CEO invest $1.7 million in company shares

Pfizer director Ronald E. Blaylock bought 39,231 shares of the company on Wednesday for $998,821, paying $25.46 per share. The shares are now trading up about 2.7 % to a high of $26.15, giving Blaylock a profit of roughly $2.9 million on the purchase. Pfizer shares are up 0.3 % on Thursday, adding to the positive momentum.

The move comes as Pfizer’s stock has been on a steady climb, buoyed by new vaccine contracts and a steady pipeline of oncology drugs. Analysts say insider buying can signal confidence in a company’s future prospects. Blaylock, who heads Pfizer’s corporate development, has a long track record of steering acquisitions and strategic partnerships that have driven the company’s growth. His purchase may reinforce investor belief that the company’s current strategy will pay off.

On Tuesday, Gbank Financial Holdings’ president and chief executive officer Jeffrey K. Newgard purchased 32,263 shares for $699,025, paying $21.67 each. The shares are now trading up 4.7 % on Thursday, showing a stronger market response than Pfizer. Newgard’s investment comes at a time when Gbank is expanding its digital banking platform and securing new regulatory approvals. The CEO’s stake suggests he believes the company’s growth trajectory will continue to accelerate.

Both insider purchases could influence investor sentiment. If the companies continue to perform well, the stock may attract more buying from other investors. Market watchers will keep an eye on earnings reports and product launches over the next quarter. The insider trades also underscore a broader trend of executives buying shares when they see upside potential, which can reassure shareholders about the company’s direction.